Cambridge Investment Research Advisors
MRNA icon

Cambridge Investment Research Advisors’s Moderna MRNA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
16,677
+100
+0.6% +$5.17K ﹤0.01% 2154
2026
Q1 		$842K Sell
16,577
-2,014
-11% -$94K ﹤0.01% 2324
2025
Q4 		$548K Sell
18,591
-4,125
-18% -$112K ﹤0.01% 2634
2025
Q3 		$587K Buy
22,716
+3,660
+19% +$102K ﹤0.01% 2520
2025
Q2 		$526K Sell
19,056
-1,824
-9% -$48K ﹤0.01% 2507
2025
Q1 		$592K Sell
20,880
-2,060
-9% -$73.1K ﹤0.01% 2267
2024
Q4 		$954K Buy
22,940
+2,064
+10% +$98.6K ﹤0.01% 1914
2024
Q3 		$1.4M Sell
20,876
-3,574
-15% -$328K ﹤0.01% 1608
2024
Q2 		$2.9M Sell
24,450
-1,336
-5% -$169K 0.01% 1051
2024
Q1 		$2.75M Buy
25,786
+2,605
+11% +$263K 0.01% 1080
2023
Q4 		$2.31M Sell
23,181
-6,329
-21% -$532K 0.01% 1119
2023
Q3 		$3.05M Sell
29,510
-10,434
-26% -$1.16M 0.01% 915
2023
Q2 		$4.85M Sell
39,944
-15,927
-29% -$2.12M 0.02% 678
2023
Q1 		$8.58M Buy
55,871
+14,560
+35% +$2.4M 0.04% 415
2022
Q4 		$7.42M Buy
41,311
+2,797
+7% +$457K 0.04% 442
2022
Q3 		$4.55M Sell
38,514
-1,779
-4% -$270K 0.03% 612
2022
Q2 		$5.76M Buy
40,293
+6,108
+18% +$873K 0.03% 527
2022
Q1 		$5.89M Sell
34,185
-4,064
-11% -$684K 0.03% 567
2021
Q4 		$9.71M Sell
38,249
-20,059
-34% -$5.86M 0.04% 388
2021
Q3 		$22.4M Buy
58,308
+18,296
+46% +$6.75M 0.11% 189
2021
Q2 		$9.4M Sell
40,012
-11,721
-23% -$2.09M 0.05% 388
2021
Q1 		$6.77M Buy
51,733
+458
+0.9% +$66.4K 0.04% 459
2020
Q4 		$5.36M Sell
51,275
-18,720
-27% -$1.89M 0.03% 505
2020
Q3 		$4.95M Buy
69,995
+6,255
+10% +$436K 0.03% 467
2020
Q2 		$4.09M Sell
63,740
-171,556
-73% -$9.4M 0.03% 505
2020
Q1 		$7.05M Sell
235,296
-109,295
-32% -$2.51M 0.07% 272
2019
Q4 		$6.74M Sell
344,591
-49,810
-13% -$884K 0.05% 363
2019
Q3 		$6.28M Buy
+394,401
New +$5.83M 0.06% 335

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Cambridge Investment Research Advisors's MRNA Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Moderna (MRNA) stake by 0.6% in Q2 2026, buying an estimated $5.17K and bringing the position to 16,677 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Cambridge Investment Research Advisors first reported a position in MRNA in Q3 2019 and has held it in 28 quarters since. The position peaked at $22.4M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Cambridge Investment Research Advisors held 16,677 shares of Moderna worth $1.17M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 100 Moderna shares in Q2 2026, an estimated $5.17K.
  • Moderna made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2154 holding.
  • Cambridge Investment Research Advisors first reported a position in Moderna in Q3 2019 and has held it in 28 quarters since.
  • Cambridge Investment Research Advisors's Moderna position peaked at $22.4M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.